secwatch / observer
8-K filed October 30, 2023, 7:59 PM ET ticker SSKN CIK 0001051514
leadership confidence high sentiment neutral materiality 0.75

Bob Moccia steps down as CEO; Dolev Rafaeli appointed President & CEO; reverse split approved

STRATA Skin Sciences, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Moccia

Member of the Board of Directors
SSKN · STRATA Skin Sciences, Inc.
Effective
2023-10-30
Filed
October 30, 2023, 7:59 PM ET
Moccia resigned as the Company’s Chief Executive Officer and President and as a member of the Company’s board of directors.
Departed

Robert Moccia

Chief Executive Officer and President
SSKN · STRATA Skin Sciences, Inc.
Effective
2023-10-30
Successor
Dolev Rafaeli
Filed
October 30, 2023, 7:59 PM ET
Moccia resigned as the Company’s Chief Executive Officer and President and as a member of the Company’s board of directors.
Appointed

Dolev Rafaeli

Vice-Chairman of the Board, President and Chief Executive Officer
SSKN · STRATA Skin Sciences, Inc.
Effective
2023-10-30
Filed
October 30, 2023, 7:59 PM ET
the Company appointed Dr. Dolev Rafaeli, PhD, (“Rafaeli”), as its Vice-Chairman of the Board, President and Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Moccia resigned as Member of the Board of Directors at STRATA Skin Sciences, Inc..

Action
resigned
Role
Member of the Board of Directors
Exact text from the filing
Moccia resigned as the Company’s Chief Executive Officer and President and as a member of the Company’s board of directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Moccia resigned as Chief Executive Officer and President at STRATA Skin Sciences, Inc..

Action
resigned
Role
Chief Executive Officer and President
Exact text from the filing
Moccia resigned as the Company’s Chief Executive Officer and President and as a member of the Company’s board of directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dolev Rafaeli was appointed as Vice-Chairman of the Board, President and Chief Executive Officer at STRATA Skin Sciences, Inc..

Action
appointed
Role
Vice-Chairman of the Board, President and Chief Executive Officer
Exact text from the filing
the Company appointed Dr. Dolev Rafaeli, PhD, (“Rafaeli”), as its Vice-Chairman of the Board, President and Chief Executive Officer.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

STRATA Skin Sciences, Inc. shareholders approved Advisory vote to approve compensation of the named executive officers at the 2023-10-26 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-10-26
Exact text from the filing
The advisory vote to approve the compensation of the Company’s named executive officers was approved. Votes For Votes Against Abstain Broker Non-Vote 24,094,572 1,372,175 22,842 4,225,530
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

STRATA Skin Sciences, Inc. shareholders approved Advisory vote on the frequency of future advisory votes to approve compensation of named executive officers at the 2023-10-26 meeting.

Proposal
say on pay frequency
Outcome
passed
Meeting
2023-10-26
Exact text from the filing
The advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers was approved. One Year Two Years Three Years Abstain 11,807,110 55,248 13,612,361 14,886
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

STRATA Skin Sciences, Inc. shareholders approved Election of the five director nominees named in the proxy statement at the 2023-10-26 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-10-26
Exact text from the filing
each of the director’s nominees to the Company’s board of directors was elected: Nominees Votes For Votes Withheld Broker Non-Vote Uri Geiger 24,964,683 524,910 4,225,530 Irit Yaniv 24,962,618 526,987 4,225,530 Wayne Cafran 25,157,665 331,940 4,225,530 Shmuel Rubinstein 24,969,443 520,150 4,225,530 Robert Moccia 23,978264 1,511,341 4,225,530
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

STRATA Skin Sciences, Inc. shareholders approved Ratification of the selection of Marcum, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-10-26 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-10-26
Exact text from the filing
Ratification of the selection by the Audit Committee or the Board of Directors of Marcum, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved. Votes For Votes Against Abstain Broker Non-Vote 29,594,033 104,833 16,269 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

STRATA Skin Sciences, Inc. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split of common stock at a ratio not less than 1-for-5 and no greater than 1-for-25 at the 2023-10-26 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2023-10-26
Exact text from the filing
The amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of its common stock at a reverse stock split ratio not less than 1-for-5, and no greater than 1-for-25 with the exact split ratio, it approved and effected at all, to be set within that range at the discretion of the Board and publicly announced by the Company within 6 months after stockholder approval at the Annual Meeting without further approval or authorization of the Company’s Stockholders was approved. Votes For Votes Against Abstain Broker Non-Vote 29,015,257 643,214 56,652 0
View on SEC.gov

224 shareholder votes filed in the last 30 days. Browse all shareholder votes →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR
accession 0001140361-23-050058
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.